WHO Essential Medicines List for cancer
The World Health Organization's list of medicines every health system should provide, which now includes about 60 cancer drugs from cyclophosphamide and cisplatin to trastuzumab, imatinib and PD-1 inhibitors, guiding procurement and pricing in lower-income countries.
The Essential Medicines List (EML, since 1977) added a systematic cancer section in 2015 (16 new medicines including trastuzumab, rituximab, imatinib), and subsequent revisions (2017, 2019, 2021, 2023, 2025) added targeted agents and, in 2023-25, PD-1 inhibitors (pembrolizumab, nivolumab, and biosimilars/generics of TKIs), CDK4/6 inhibitors (2025 for breast cancer), enzalutamide, and paediatric formulations; some high-cost agents (e.g. some ADCs) were declined on cost-effectiveness grounds. Listing is a signal to governments, procurement agencies (UNICEF, Global Fund models) and generic manufacturers, and underpins efforts like the Access to Oncology Medicines Coalition. The children's EML (EMLc) covers paediatric protocols; the WHO Model Formulary and prequalification of biosimilars (trastuzumab, rituximab 2019-20) support access.
Pages like this
not linked directly; found by shared links- TermOncology workforce
Shares Global oncology and access in low- and middle-income countries and the tags gap-fill, policy.
- CancerKaposi sarcoma
Shares Global oncology and access in low- and middle-income countries, Pembrolizumab and the tags gap-fill, global.
- TermFinancial toxicity
Shares Oncology drug pricing and price transparency and the tag gap-fill.
- TechnologyAntiemetics for chemotherapy-induced nausea and vomiting
Shares Low-dose olanzapine for cancer anorexia (Tata Memorial), Cisplatin and the tag gap-fill.
- TechnologyElectrochemotherapy
Shares Cisplatin and the tag gap-fill.
- TechnologyTelehealth and hospital-at-home in oncology
Shares Global oncology and access in low- and middle-income countries and the tag gap-fill.
- TargetPDGFRA
Shares Imatinib and the tag gap-fill.
- CancerThymoma and thymic carcinoma
Shares Cyclophosphamide, Cisplatin, Imatinib, Pembrolizumab and the tag gap-fill.